95 related articles for article (PubMed ID: 28434353)
1. A novel murine system for validating the specific targeting of peptides to light chain associated (AL) amyloid.
Beierle SP; Foster JS; Richey T; Stuckey A; Macy S; Kennel SJ; Wall JS
Amyloid; 2017 Mar; 24(sup1):74-75. PubMed ID: 28434353
[No Abstract] [Full Text] [Related]
2. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
4. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
[TBL] [Abstract][Full Text] [Related]
5. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis.
Wall JS; Martin EB; Richey T; Stuckey AC; Macy S; Wooliver C; Williams A; Foster JS; McWilliams-Koeppen P; Uberbacher E; Cheng X; Kennel SJ
Molecules; 2015 Apr; 20(5):7657-82. PubMed ID: 25923515
[TBL] [Abstract][Full Text] [Related]
7. Effect of single point mutations in a form of systemic amyloidosis.
Bhavaraju M; Hansmann UH
Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812
[TBL] [Abstract][Full Text] [Related]
8. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.
Wall JS; Richey T; Stuckey A; Donnell R; Macy S; Martin EB; Williams A; Higuchi K; Kennel SJ
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):E586-94. PubMed ID: 21807994
[TBL] [Abstract][Full Text] [Related]
9. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
Morgan GJ
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
[TBL] [Abstract][Full Text] [Related]
10. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
[TBL] [Abstract][Full Text] [Related]
11. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
[TBL] [Abstract][Full Text] [Related]
12. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
13. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody.
Wall JS; Kennel SJ; Paulus M; Gregor J; Richey T; Avenell J; Yap J; Townsend D; Weiss DT; Solomon A
J Nucl Med; 2006 Dec; 47(12):2016-24. PubMed ID: 17138745
[TBL] [Abstract][Full Text] [Related]
14. Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants.
Wall JS; Williams A; Richey T; Stuckey A; Wooliver C; Christopher Scott J; Donnell R; Martin EB; Kennel SJ
Mol Imaging Biol; 2017 Oct; 19(5):714-722. PubMed ID: 28229334
[TBL] [Abstract][Full Text] [Related]
15. Measurement of liver and spleen interstitial volume in patients with systemic amyloid light-chain amyloidosis using equilibrium contrast CT.
Yeung J; Sivarajan S; Treibel TA; Rosmini S; Fontana M; Gillmore JD; Hawkins PN; Punwani S; Moon JC; Taylor SA; Bandula S
Abdom Radiol (NY); 2017 Nov; 42(11):2646-2651. PubMed ID: 28567484
[TBL] [Abstract][Full Text] [Related]
16. Assays for Light Chain Amyloidosis Formation and Cytotoxicity.
Blancas-Mejia LM; Misra P; Dick CJ; Marin-Argany M; Redhage KR; Cooper SA; Ramirez-Alvarado M
Methods Mol Biol; 2019; 1873():123-153. PubMed ID: 30341607
[TBL] [Abstract][Full Text] [Related]
17. 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.
Park MA; Padera RF; Belanger A; Dubey S; Hwang DH; Veeranna V; Falk RH; Di Carli MF; Dorbala S
Circ Cardiovasc Imaging; 2015 Aug; 8(8):. PubMed ID: 26259579
[TBL] [Abstract][Full Text] [Related]
18. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
[TBL] [Abstract][Full Text] [Related]
19. The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis.
Oberti L; Maritan M; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Palladini G; Bolognesi M; Merlini G; Ricagno S
Amyloid; 2019; 26(sup1):107-108. PubMed ID: 31343357
[No Abstract] [Full Text] [Related]
20. Recruitment of Light Chains by Homologous and Heterologous Fibrils Shows Distinctive Kinetic and Conformational Specificity.
Blancas-Mejía LM; Ramirez-Alvarado M
Biochemistry; 2016 May; 55(21):2967-78. PubMed ID: 27158939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
